Step 1 topics → Biochemistry → CRISPR and Gene Therapy Concepts

CRISPR and Gene Therapy Concepts

USMLE Step 1 trap: Confuses NHEJ (default, error-prone) with HDR (precise, template-dependent) as the default CRISPR repair outcome. CRISPR-Cas9 cuts DNA and the default repair pathway is error-prone NHEJ, which causes insertions/deletions (indels) and gene disruption; HDR requires a donor template and is less common.

CRISPR-Cas9 and gene therapy sit at the intersection of molecular biology and clinical medicine — and while this is a low-yield topic on USMLE Step 1, it shows up in vignette stems that describe emerging treatments for diseases like sickle cell, beta-thalassemia, or inherited blindness. The exam doesn't ask you to design a CRISPR experiment, but it does expect you to understand the mechanism well enough to reason through what happens when DNA gets cut, which repair pathway activates, and why a given clinical outcome (gene knockout vs. gene correction) follows. The other angle is viral vectors: knowing which vector does what in the context of an approved therapy.

What makes this tricky is that students conflate the goal of CRISPR (precision editing) with what actually happens by default. Most people assume that cutting DNA leads to clean correction — it doesn't. The default repair pathway after a double-strand break is NHEJ, which is fast, sloppy, and creates indels. Precise correction via HDR only happens when you supply a donor template, and even then it's inefficient. USMLE Step 1 will reward students who understand this mechanistic distinction, not just the headline 'CRISPR edits genes.'

The viral vector misconception is equally common: students lump all gene therapy vectors together as 'integrating,' but AAV — the workhorse of approved gene therapies like those for spinal muscular atrophy and inherited retinal dystrophy — stays largely episomal. Retroviruses and lentiviruses integrate, which is why they carry insertional mutagenesis risk. That distinction matters clinically and mechanistically, and it's exactly the kind of nuance the exam probes in passage-based questions.

From real student decks
35%have cards covering this topic
22%have mature cards

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake
Wrong: CRISPR-Cas9 always results in precise gene correction via homology-directed repair.
Right: CRISPR-Cas9 cuts DNA and the default repair pathway is error-prone NHEJ, which causes insertions/deletions (indels) and gene disruption; HDR requires a donor template and is less common.
CRISPR-Cas9 is a precision tool for targeting, but cutting DNA does not automatically mean precise repair. When Cas9 creates a double-strand break, the cell defaults to NHEJ — a fast but error-prone pathway that often introduces small insertions or deletions (indels), disrupting the reading frame and knocking out gene function. HDR can achieve precise sequence correction, but it requires a supplied donor template and occurs far less frequently; thinking of CRISPR as inherently corrective misses the fact that most CRISPR experiments are designed to exploit NHEJ-mediated disruption, not correction.
Common mistake
Wrong: Cas9 protein alone finds and cuts the target DNA sequence.
Right: Cas9 is directed to its target by a guide RNA (gRNA) that base-pairs with the complementary DNA strand adjacent to a PAM sequence.
Cas9 is an endonuclease — it can cut DNA — but it has no intrinsic sequence specificity on its own. The guide RNA is what gives CRISPR its addressability: the gRNA contains a ~20-nucleotide sequence that base-pairs with the complementary target DNA strand, and Cas9 only cuts when this gRNA-DNA pairing is adjacent to a PAM sequence. Without the gRNA, Cas9 is a non-specific cutter; swapping the gRNA sequence is literally how you retarget the system to a new genomic locus.
Common mistake
Wrong: All viral vectors used in gene therapy integrate permanently into the host genome.
Right: Adeno-associated virus (AAV) vectors, the most commonly used in approved therapies, remain largely episomal and do not integrate, while retroviruses/lentiviruses do integrate.
Not all viral vectors behave like retroviruses. AAV (adeno-associated virus) is the most widely used vector in currently approved gene therapies — it efficiently transduces post-mitotic cells (like neurons, retinal cells, muscle) and its DNA persists primarily as an episome in the nucleus rather than integrating into chromosomal DNA. This episomal persistence means AAV-delivered genes can be diluted out in rapidly dividing cells, but it also means lower insertional mutagenesis risk compared to retroviruses and lentiviruses, which stably integrate and can disrupt host genes near the insertion site.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Understand the two-component CRISPR-Cas9 system: know that guide RNA (gRNA) directs Cas9 to a specific DNA target via complementary base-pairing adjacent to a PAM sequence, and that Cas9 alone cannot find its target — the exam will test whether you know the role of gRNA versus Cas9.
  2. Distinguish what happens after CRISPR creates a double-strand break: NHEJ is the default repair pathway and produces indels (gene disruption/knockout), while HDR produces precise correction but only when a donor template is provided — be able to predict the repair outcome based on experimental conditions.
  3. Know the key properties of viral vectors used in gene therapy: AAV vectors are episomal (non-integrating) and used in most approved therapies, while retroviruses and lentiviruses integrate into the host genome and carry insertional mutagenesis risk — connect vector type to mechanism and safety profile.

Can you avoid these mistakes?

A researcher uses CRISPR-Cas9 to target a gene in cell culture but does NOT provide a donor template. What is the most likely repair outcome, and what functional consequence does this have for the targeted gene?
You swap out the guide RNA in a CRISPR construct but keep the same Cas9 protein. What changes, and what stays the same about the system's activity?
A patient with an inherited retinal dystrophy receives a gene therapy delivered by AAV vector. A classmate says this means the corrected gene is now permanently integrated in every retinal cell. What's wrong with this statement, and how does AAV differ from a lentiviral vector?
A clinical trial uses CRISPR to disrupt the BCL11A gene in hematopoietic stem cells from a sickle cell patient. This approach relies on which repair pathway — NHEJ or HDR — and why is that pathway appropriate here given the goal is to knock out BCL11A function rather than correct the HBB mutation directly?

Related topics

DNA Repair Pathways Nucleotide and Nucleic Acid Structure DNA Replication Mutations and Their Consequences

See how your Anki deck covers this topic.

Upload your deck for a free audit →